The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Vandetanib Gemcitabine Or Placebo Plus Gemcitabine Or Vandetanib Monotherapy In Advanced Biliary Tract Cancer
Official Title: A Randomized, Multicentre, Phase II, Parallel-Group Trial of Vandetanib Monotherapy or Vandetanib in Combination With Gemcitabine Versus Gemcitabine Plus Vandetanib Matching Placebo in Subjects With Advanced Biliary Tract Cancer (Gallbladder Cancer, Cancer of the Extrahepatic Bile Duct, Intrahepatic Cholangiocarcinoma and Ampullary Carcinoma)
Study ID: NCT00753675
Brief Summary: The primary objective of the trial is to determine the efficacy of VANDETANIB monotherapy or VANDETANIB plus GEMCITABINE or PLACEBO plus GEMCITABINE in prolonging the progression-free survival (PFS) at the trial closure in patients with advanced (unresectable or metastatic) biliary tract cancer.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Research Site, Brescia, BS, Italy
Research Site, Firenze, FI, Italy
Research Site, Genova, GE, Italy
Research Site, Milano, Mi, Italy
Research Site, Palermo, PA, Italy
Research Site, Aviano, PN, Italy
Research Site, Parma, PR, Italy
Research Site, Reggio Emilia, RE, Italy
Research Site, Ancona, , Italy
Research Site, Livorno, , Italy
Research Site, Napoli, , Italy
Research Site, Pisa, , Italy
Research Site, Ravenna, , Italy
Research Site, Rho, , Italy
Research Site, Torino, , Italy
Name: Clinical Sciences & Operations
Affiliation: Sanofi
Role: STUDY_DIRECTOR